Emcitate (tiratricol)

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

43 evidence topics · 14 sources

Current treatment options and standard of care23 evidence topics · 8 sources
Place in treatment, anticipated use, and care setting4 evidence topics · 8 sources
Heterogeneity of treatment effect3 evidence topics · 3 sources
Care management intervention strategies4 evidence topics · 3 sources
Other product development or post-marketing obligations required by the FDA1 evidence topic · 1 source
Ongoing post-approval monitoring5 evidence topics · 2 sources
Expected outcomes of therapy3 evidence topics · 2 sources